From bacterial genomes to novel antibacterial agents: Discovery, characterization, and antibacterial activity of compounds that bind to HI0065 (YjeE) from Haemophilus influenzae

Chemical Biology and Drug Design

Volumn 69, Issue 6, 2007, Pages 395-404

  Lerner, Claude G ^a   Hajduk, Philip J ^a   Wagner, Rolf ^a   Wagenaar, Frank L ^a   Woodall, Charlotte ^a   Gu, Yu Gui ^a   Searle, Xenia B ^a   Florjancic, Alan S ^a   Zhang, Tianyuan ^a   Clark, Richard F ^a   Cooper, Curt S ^a   Mack, Jamey C ^a   Yu, Liping ^a   Cai, Mengli ^a   Betz, Steven F ^a   Chovan, Linda E ^a   McCall, J Owen ^a   Black Schaefer, Candace L ^a   Kakavas, Stephan J ^a   Schurdak, Mark E ^a   Comess, Kenneth M ^a   Walter, Karl A ^a   Edalji, Rohinton ^a   Dorwin, Sarah A ^a   Smith, Richard A ^a   Hebert, Eric J ^a   Harlan, John E ^a   Metzger, Randy E ^a   Merta, Philip J ^a   Baranowski, John L ^a   Coen, Michael L ^a   Thornewell, Susan J ^a   Shivakumar, Annapur G ^a   Saiki, Anne Y ^a   Soni, Niru ^a   Bui, Mai ^a   Balli, Darlene J ^a   Sanders, William J ^a   Nilius, Angela M ^a   Holzman, Thomas F ^a   Fesik, Stephen W ^a   Beutel, Bruce A ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

Drug Discovery; NMR screening

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIINFECTIVE AGENT; BINDING PROTEIN; GENE PRODUCT; HI0065 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; B LYMPHOCYTE; BACTERIAL GENOME; BACTERIUM; BINDING AFFINITY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG MECHANISM; EUKARYOTIC CELL; HAEMOPHILUS INFLUENZAE; MASS SPECTROMETRY; MICROBIAL VIABILITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN TARGETING; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATASES; AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; B-LYMPHOCYTES; BACTERIAL PROTEINS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; GENOME, BACTERIAL; GENOMICS; HAEMOPHILUS INFLUENZAE; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); EUKARYOTA; HAEMOPHILUS INFLUENZAE; STAPHYLOCOCCUS AUREUS;

EID: 34250788831     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00521.x     Document Type: Article

References (62)

1. Livermore D.M. (2003) Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 36 : S11 S23.
2. Livermore D.M. (2004) The need for new antibiotics. Clin Microbiol Infect 10 (Suppl. 4 1 9.
3. Levy S.B., Marshall B. (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10 : S122 S129.
4. Bush K. (2004) Antibacterial drug discovery in the 21st century. Clin Microbiol Infect 10 (Suppl. 4 10 17.
5. Fauci A.S. (2001) Infectious diseases: considerations for the 21st century. Clin Infect Dis 32 : 675 685.
6. Rice L.B. (2003) Do we really need new anti-infective drugs Curr Opin Pharmacol 3 : 459 463.
7. Payne D.J., Gwynn M.N., Holmes D.J., Rosenberg M. (2004) Genomic approaches to antibacterial discovery. Methods Mol Biol 266 : 231 259.
8. Chalker A.F., Lunsford R.D. (2002) Rational identification of new antibacterial drug targets that are essential for viability using a genomics-based approach. Pharmacol Ther 95 : 1 20.
9. Glass J.I., Belanger A.E., Robertson G.T. (2002) Streptococcus pneumoniae as a genomics platform for broad-spectrum antibiotic discovery. Curr Opin Microbiol 5 : 338 342.
10. Lerner C.G., Beutel B.A. (2002) Antibacterial drug discovery in the post-genomics era. Curr Drug Targets Infect Disord 2 : 109 119.
11. Johnson K.W., Lofland D., Moser H.E. (2005) PDF inhibitors: an emerging class of antibacterial drugs. Curr Drug Targets Infect Disord 5 : 39 52.
12. Jain R., Chen D., White R.J., Patel D.V., Yuan Z. (2005) Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr Med Chem 12 : 1607 1621.
13. Boggs A.F., Hecker S.J. (2003) A tour of recent patent applications addressing antibacterial resistance. Expert Opin Ther Patents 12 : 1159 1172.
14. Payne D.J., Warren P.V., Holmes D.J., Ji Y., Lonsdale J.T. (2001) Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Discov Today 6 : 537 544.
15. Hajduk P.J., Gerfin T., Boehlen J.M., Haberli M., Marek D., Fesik S.W. (1999) High-throughput nuclear magnetic resonance-based screening. J Med Chem 42 : 2315 2317.
16. Kelly M.A., McLellan T.J., Rosner P.J. (2002) Strategic use of affinity-based mass spectrometry techniques in the drug discovery process. Anal Chem 74 : 1 9.
17. Comess K.M., Schurdak M.E. (2004) Affinity-based screening techniques for enhancing lead discovery. Curr Opin Drug Discov Devel 7 : 411 416.
18. Qian J., Voorbach M.J., Huth J.R., Coen M.L., Zhang H., Ng S.C., Comess K.M., Petros A.M., Rosenberg S.H., Warrior U., Burns D.J. (2004) Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. Anal Biochem 328 : 131 138.
19. Hajduk P.J., Betz S.F., Mack J., Ruan X., Towne D.L., Lerner C.G., Beutel B.A., Fesik S.W. (2002) A strategy for high-throughput assay development using leads derived from nuclear magnetic resonance-based screening. J Biomol Screen 7 : 429 432.
20. Link A.J., Phillips D., Church G.M. (1997) Methods for generating precise deletions and insertions in the genome of wild-type Escherichia coli: application to open reading frame characterization. J Bacteriol 179 : 6228 6237.
21. Yu L., Gunasekera A.H., Mack J., Olejniczak E.T., Chovan L.E., Ruan X., Towne D.L., Lerner C.G., Fesik S.W. (2001) Solution structure and function of a conserved protein SP14.3 encoded by an essential Streptococcus pneumoniae gene. J Mol Biol 311 : 593 604.
22. Reich K.A., Chovan L., Hessler P. (1999) Genome scanning in Haemophilus influenzae for identification of essential genes. J Bacteriol 181 : 4961 4968.
23. Hajduk P.J., Augeri D.A., Mack J., Mendoza R., Yang J., Betz S.F., Fesik S.W. (2000) NMR-based screening of proteins containing 13C-labeled methyl groups. J Med Chem 122 : 7898 7904.
24. Goto N.K., Gardner K.H., Mueller G.A., Willis R.C., Kay L.E. (1999) A robust and cost-effective method for the production of Val, Leu, Ile (delta 1) methyl-protonated N-15, C-13, H-2-labeled proteins. J Biomol NMR 13 : 369 374.
25. Stonehouse J., Shaw G.L., Keeler J., Laue E.D. (1994) Minimizing sensitivity losses in gradient-selected 15N-1H HSQC spectra of proteins. J Magn Reson 107 : 178 184.
26. Piotto M., Saudek V., Sklenar V. (1992) Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J Biomol NMR 2 : 661 665.
27. Epps D.E., Raub T.J., Caiolfa V., Chiari A., Zamai M. (1999) Determination of the affinity of drugs toward serum albumin by measurement of the quenching of the intrinsic tryptophan fluorescence of the protein. J Pharm Pharmacol 51 : 41 48.
28. Seals J.R., McDonald J.M., Bruns D., Jarett L. (1978) A sensitive and precise isotopic assay of ATPase activity. Anal Biochem 90 : 785 795.
29. Clinical Laboratory Standards Institute (2006) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. M7-A4. Wayne, PA : Clinical Laboratory Standards Institute.
30. Mikus J., Steverding D. (2000) A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol Int 48 : 265 269.
31. Schmid M.B. (2001) Microbial genomics - new targets, new drugs. Expert Opin Ther Targets 5 : 465 475.
32. Schmid M.B. (2004) Seeing is believing: the impact of structural genomics on antimicrobial drug discovery. Nat Rev Microbiol 2 : 739 746.
33. Brown E.D., Wright G.D. (2005) New targets and screening approaches in antimicrobial drug discovery. Chem Rev 105 : 759 774.
34. Galperin M.Y., Koonin E.V. (1999) Searching for drug targets in microbial genomes. Curr Opin Biotechnol 10 : 571 578.
35. Loferer H. (2000) Mining bacterial genomes for antimicrobial targets. Mol Med Today 6 : 470 474.
36. McDevitt D., Rosenberg M. (2001) Exploiting genomics to discover new antibiotics. Trends Microbiol 9 : 611 617.
37. Yin D., Fox B., Lonetto M.L., Etherton M.R., Payne D.J., Holmes D.J., Rosenberg M., Ji Y. (2004) Identification of antimicrobial targets using a comprehensive genomic approach. Pharmacogenomics 5 : 101 113.
38. Rosamond J., Allsop A. (2000) Harnessing the power of the genome in the search for new antibiotics. Science 287 : 1973 1976.
39. Moir D.T., Shaw K.J., Hare R.S., Vovis G.F. (1999) Genomics and antimicrobial drug discovery. Antimicrob Agents Chemother 43 : 439 446.
40. Thanassi J.A., Hartman-Neumann S.L., Dougherty T.J., Dougherty B.A., Pucci M.J. (2002) Identification of 113 conserved essential genes using a high-throughput gene disruption system in Streptococcus pneumoniae. Nucleic Acids Res 30 : 3152 3162.
41. Mills S.D. (2003) The role of genomics in antimicrobial discovery. J Antimicrob Chemother 51 : 749 752.
42. Volker C., Brown J.R. (2002) Bioinformatics and the discovery of novel anti-microbial targets. Curr Drug Targets Infect Disord 2 : 279 290.
43. Akerley B.J., Rubin E.J., Novick V.L., Amaya K., Judson N., Mekalanos J.J. (2002) A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc Natl Acad Sci U S A 99 : 966 971.
44. Hare R.S., Walker S.S., Dorman T.E., Greene J.R., Guzman L.M., Kenney T.J., Sulavik M.C., Baradaran K., Houseweart C., Yu H., Foldes Z., Motzer A., Walbridge M., Shimer G.H. Jr., Shaw K.J. (2001) Genetic footprinting in bacteria. J Bacteriol 183 : 1694 1706.
45. Zalacain M., Biswas S., Ingraham K.A., Ambrad J., Bryant A., Chalker A.F., Iordanescu S. et al. (2003) A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function. J Mol Microbiol Biotechnol 6 : 109 126.
46. Fleischmann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F., Kerlavage A.R., Bult C.J. et al. (1995) Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269 : 496 512.
47. Tettelin H., Nelson K.E., Paulsen I.T., Eisen J.A., Read T.D., Peterson S., Heidelberg J. et al. (2001) Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 293 : 498 506.
48. Hoskins J., Alborn W.E. Jr., Arnold J., Blaszczak L.C., Burgett S., DeHoff B.S., Estrem S.T. et al. (2001) Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol 183 : 5709 5717.
49. Rost B. (1999) Twilight zone of protein sequence alignments. Protein Eng 12 : 85 94.
50. Sanders W.J., Nienaber V.L., Lerner C.G., McCall J.O., Merrick S.M., Swanson S.J., Harlan J.E. et al. (2004) Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. J Med Chem 47 : 1709 1718.
51. Gu Y.G., Florjancic A.S., Clark R.F., Zhang T., Cooper C.S., Anderson D.D., Lerner C.G., McCall J.O., Cai Y., Black-Schaefer C.L., Stamper G.F., Hajduk P.J., Beutel B.A. (2004) Structure-activity relationships of novel potent MurF inhibitors. Bioorg Med Chem Lett 14 : 267 270.
52. Stamper G.F., Longenecker K.L., Fry E.H., Jakob C.G., Florjancic A.S., Gu Y.G., Anderson D.D. et al. (2006) Structure-based optimization of MurF inhibitors. Chem Biol Drug Des 67 : 58 65.
53. Bairoch A., Apweiler R., Wu C.H., Barker W.C., Boeckmann B., Ferro S., Gasteiger E., Huang H., Lopez R., Magrane M., Martin M.J., Natale D.A., O'Donovan C., Redaschi N., Yeh L.S. (2005) The Universal Protein Resource (UniProt). Nucleic Acids Res 33 : D154 D159.
54. Freiberg C., Wieland B., Spaltmann F., Ehlert K., Brotz H., Labischinski H. (2001) Identification of novel essential Escherichia coli genes conserved among pathogenic bacteria. J Mol Microbiol Biotechnol 3 : 483 489.
55. Kobayashi K., Ehrlich S.D., Albertini A., Amati G., Andersen K.K., Arnaud M., Asai K. et al. (2003) Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A 100 : 4678 4683.
56. Walker J.E., Saraste M., Runswick M.J., Gay N.J. (1982) Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1 : 945 951.
57. Allali-Hassani A., Campbell T.L., Ho A., Schertzer J.W., Brown E.D. (2004) Probing the active site of YjeE: a vital Escherichia coli protein of unknown function. Biochem J 384 : 577 584.
58. Teplyakov A., Obmolova G., Tordova M., Thanki N., Bonander N., Eisenstein E., Howard A.J., Gilliland G.L. (2002) Crystal structure of the YjeE protein from Haemophilus influenzae: a putative ATPase involved in cell wall synthesis. Proteins 48 : 220 226.
59. Epps D.E., Raub T.J., Hezdy F.J. (1995) A general wide-range spectrofluorometric method for measuring the site-specific affinities of drugs toward human serum albumin. Anal Biochem 227 : 342 350.
60. Mao H., Hajduk P.J., Craig R., Bell R., Borre T., Fesik S.W. (2001) Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc 123 : 10429 10435.
61. Hajduk P.J., Mendoza R., Petros A.M., Huth J.R., Bures M., Fesik S.W., Martin Y.C. (2003) Ligand binding to domain-3 of human serum albumin: a chemometric analysis. J Comput Aided Mol Des 17 : 93 102.
62. Garcia-Lara J., Masalha M., Foster S.J. (2005) Staphylococcus aureus: the search for novel targets. Drug Discov Today 10 : 643 651.